/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
With nearly two decades of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life.
$4.43
$0.12 (-2.64%)
Live · 09:32 PM
15.26% operating margin is respectable but not wide. ROIC at 18.59%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue grew 20.0%, still solid.
At 111x earnings, the current multiple leaves limited room for execution misses or growth deceleration. ROIC dropped from 21.14% to 18.59%, capital efficiency is deteriorating.
110.7x earnings. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$355M
▲ +20.0% YoY
Net Income (TTM)
$6M
▲ +14.5% YoY
Op. Margin
2.46%
▼ -1.6pp YoY
ROIC
2.68%
▼ -2.5pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
$46M
▲ +11.8% YoY
Net Debt
-$119M
Net Cash Position
Cash & Equiv.
$136M
5Y CAGR: +11.0%
Continue Research
SourceComputed from the 10-Q filed 29 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 3 Aug 2026. How this is calculated.
Price from market data, live as of 3 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
At a P/E of 110.7, MiMedx Group (MDXG) trades around a two-stage DCF intrinsic value of about $4.98 per share, so at $4.43 the stock looks around fair value (12.4% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, MiMedx Group scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $4.98 per share for MDXG, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $3.73. At today's $4.43, that puts the stock about 12.4% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
MiMedx Group scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 2.5% operating margin and a 2.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. MDXG currently trades around its estimated intrinsic value and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.